Cartridge-based automated BCR-ABl1 mRNA quantification: Solving the issues of standardization, at what cost?

Haematologica

Volumn 96, Issue 5, 2011, Pages 664-671

  Cayuela, Jean Michel ^a,b   Macintyre, Elizabeth ^c   Darlington, Meryl ^c   Abdelali, Raouf Ben ^c   Fund, Xavier ^a   Villarese, Patrick ^c   Tulliez, Michel ^d   Raffoux, Emmanuel ^a   Sigaux, François ^a,b   Réa, Delphine ^a   Seror, Valerie ^e  

^a SAINT LOUIS HOSPITAL   (France)

^b UNIVERSITÉ PARIS DIDEROT   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e AIX MARSEILLE UNIV   (France)

Author keywords

BCR ABL1; Chronic myeloid leukemia; Cost assessment; Real time quantitative PCR; Standardization

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB; MESSENGER RNA; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; AUTOMATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; REFERENCE VALUE; REPRODUCIBILITY; RNA ANALYSIS; SAMPLING; STANDARDIZATION;

CLINICAL LABORATORY TECHNIQUES; COSTS AND COST ANALYSIS; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 79955718578     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.034389     Document Type: Article

References (17)

1. Druker B, Guilhot F, O'Brien S, Gathmann I, Kantarjian H, Gattermann N, et al. Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408-17.
2. Hughes T, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley M, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349(15):1423-32.
3. Hughes T, Branford S, White D, Reynolds J, Koelmeyer R, Seymour J, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 2008;112(10): 3965-73.
4. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2006;108(6):1809-20.
5. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic Myeloid Leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol. 2009;27(35):6041-51.
6. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(6):28-37.
7. Branford S, Cross N, Hochhaus A, Radich J, Saglio G, Kaeda J, et al. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 2006;20(11):1925-30.
8. Branford S, Fletcher L, Cross N, Müller M, Hochhaus A, Kim D, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 2008;112(8):3330-8.
9. Winn-Deen E, Helton B, Van Atta R, Wong W, Peralta J, Wang J, et al. Development of an integrated assay for detection of BCRABL RNA. Clin Chem. 2007;53(9):1593-600.
10. Jobbagy Z, van Atta R, Murphy K, Eshleman J, Gocke C. Evaluation of the Cepheid GeneXpert BCR-ABL assay. J Mol Diagn. 2007;9(2):220-7.
11. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia. 2003;17(12):2318-57.
12. Müller M, Cross N, Erben P, Schenk T, Hanfstein B, Ernst T, et al. Harmonization of molecular monitoring of CML therapy in Europe. Leukemia. 2009;23(11):1957-63.
13. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet. 1986;1(8476):307-10.
14. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135-60.
15. Drummond M, O'Brien B, Stoddart G, Torrance G. Methods for the economic evaluation of health care programmes. 2nd edition ed. Oxford, England: Oxford University Press; 1997.
16. Luce B, Manning W, Siegel J, Lipscomb J. Estimating costs in cost-effectiveness analysis. New York: Oxford University Press; 1996.
17. Bossard N, Velten M, Memontet L, Belot A, Maarouf N, Bouvier A, et al. Survival of cancer patients in France: a populationbased study from the Association of the French Cancer Registries (FRANCIM). Eur J Cancer. 2007;43(1):149-60.